HDFC Securities
05:04 Jun 20, 2013
PRODUCTS & SERVICES
Equity & IPO
Mutual Funds
Derivative
National Pension System
NRI Offerings
Insurance
Fixed Deposit & Bonds
Loans & Realty
STOCK MARKETS
Markets Overview
IPO
Derivatives
Company Data
Stock Screener
News
Technical Chart
MUTUAL FUNDS
MF Overview
Scheme Comparison
MF News
RESEARCH
Overview
Equity
Mutual Fund
Derivative
Currency
Debt
IPO
FINANCIAL TOOLS
EMI Calculator
FD Calculator
Retirement Calculator
Tax Planning
SIP Calculator
Set Your Target
ONLINE TRADING
Place Order
Order Book
Trade Book
Open Positions
Change Password
Fund Hold Release
Security Hold Release
Demat Balance
CUSTOMER SERVICES
Getting Started
Education
FAQs
Branch Locator
Contact Us
SENSEX
|
NIFTY
19,245.70
+22.42 (+0.12%)
Click on date to view events.
FII ACTIVITY
(For last 2 Weeks)
Global Indices
HANG SENG
20,986.89
-1.13%
19Jun (15:51)
STRAITS TIMES
3,213.79
-0.49%
19Jun (15:51)
NASDAQ
3,443.20
-1.12%
20Jun (03:00)
DJIA
15,112.19
-1.35%
20Jun (03:00)
Top Sectors (BSE 100)
TELECOMM-SERVICE
3
7
STEEL
41
4
43
AGRO CHEMICALS
9
12
PORTFOLIO
WATCHLIST
MY PAGE
LOGIN FOR
MY PAGE
NEW USER?
REGISTER HERE
Home
/
Market
/ Information
Pharmaceuticals
|
Government of India
Bharat Immunological & Biological Corporation Ltd
HSL Code: BHAIMU
| BSE Code: 524663 | NSE Symbol: N.A. | ISIN: INE994B01014
Snapshot
Key Ratios
Charting
Financials
Message Board
Announcements
peer companies
BSE
12.70
0.48(3.93%)
19 Jun 2013 | 15:32
Prev Close (Rs.)
12.22
Open (Rs.)
12.22
High (Rs.)
12.84
Low (Rs.)
12.00
Volume
9,313
Week Avg. Volume
16,839
52Wk High - Low Range
11.15
24.10
BackGround
Board of Directors
Company History
Locations
Incorporated in 1989 in Uttar Pradesh, Bharat Immunological & Biological Corporation (BIBCL) is in the business of manufacturing pharmaceutical formulations. The company`s manufacturing unit is located in Bulandshahr district, Uttar Pradesh. BIBCL manufactures oral polio vaccine (OPV) for which it has installed a plant of 100 mln units. Commercial production of the OPV started from Jan`96. The company has received firm orders for supply of OPV from the Ministry of Health and Family Welfare, Government of India, for use in the national immunisation programme. It has set up an R&D unit for the development of hepatitis B vaccine through transfer of technology from the US. The Company is planning to diversify into the production of vaccines pertaining to B.C.G, Measles and Tetanus Toxide.The company has been declared a SICK company by BIFR.
Financials
Balance Sheet
Profit & Loss
Quarterly Results
Half Yearly Results
Ratios
Information
Company History
Background
Board of Directors
Locations
Bulk Deals
Block Deals
Exchange Information
Mutual Fund Holding
Share Holding Pattern
Announcements
Research
News
BSE Announcements
NSE Announcements
Board Meetings
Dividend
AGM
EGM
Bonus
Rights
Splits
Annual Report
Directors Report
Chairman's Speech
Auditors Report
Finished Products
Raw Materials
Peer Comparison
Peer Companies
Analyst Videos Archive
Sensex
Nifty
Fetching Data...
ALERT